MAPT and Alzheimer disease: In the last study performed with participants with preclinical AD where the Aβ42/Tau ratio in cerebrospinal fluid was analyzed, it was reported that there were no significant differences between groups in terms of RNFL, ganglion cell-inner plexiform layer complex (GC-IPL), or total macular thickness, according to SD-OCT.